Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial-Reference-Cited by-同舟云学术

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

Published:2024-05 Issue: Volume:184 Page:168-177
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Pothuri Bhavana,Han Sileny,Chase Dana M.,Heitz Florian,Burger Robert A.,Gaba Lydia,Van Le Linda,Guerra Eva,Bender David,Korach Jacob,Cloven Noelle,Churruca Cristina,Follana Philippe,DiSilvestro Paul,Baurain Jean-François,Jardon Kris,Pisano Carmela,Peen Ulla,Mäenpää Johanna,Gupta Divya,Bacqué Emeline,Li Yong,Compton Natalie,Antonova Jenya,Monk Bradley J.,González-Martín Antonio

Funder

GlaxoSmithKline

Publisher

Elsevier BV

Reference31 articles.

1. Management of relapsed ovarian cancer: a review;Giornelli;Springerplus,2016

2. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy;Hanker;Ann. Oncol.,2012

3. ESMO Guidelines Committee, Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines;Colombo;Ann. Oncol.,2021

4. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease;Colombo;Ann. Oncol.,2019

5. PARP inhibitors in the management of ovarian cancer: ASCO guideline;Tew;J. Clin. Oncol.,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial;Annals of Oncology;2024-09

2. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial;Gynecologic Oncology;2024-08